ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.

Andersen G, Eloy R, Heise T, Gaudier M, Mégret C, Seroussi C, Chan YP, Soula O, Riddle M, DeVries JH

Diabetes, obesity & metabolism7 Aug 2024Cited by 4 (Europe PMC)

PMID39109464DOI10.1111/dom.15827PepBankPUB-39109464

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

01HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In participants with type 1 diabetes, ADO09 produced significant continuing weight loss of 2.1 kg relative to insulin lispro.
In plain wordsIn participants with diabetes, ADO09 reduced body weight more than insulin lispro.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight
Study
n = 80
Comparator
Insulin lispro
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Relative weight loss
2.1 kg
ADO09 versus lispro
Source sentences
Summary
In the whole group, the weight loss with ADO09 relative to lispro was 2.1 kg.
3 context sentences(design, population, supporting numbers)
Summary · context
A significant and continuing weight loss, the primary endpoint, was observed with ADO09 compared with lispro as prandial insulin.
Summary · context
To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Summary · context
A randomized, two-arm ambulatory 16-week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3910946401
02HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In participants with type 1 diabetes, glycated haemoglobin did not change during treatment in either the ADO09 or lispro group.
In plain wordsIn participants with diabetes, glycated haemoglobin did not change from baseline in either the ADO09 or lispro group.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeGlycated haemoglobin
Study
n = 80
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean glycated haemoglobin
7.7%
both groups
Source sentences
Summary
Glycaemic control was relatively good (7.7% mean glycated haemoglobin) in both groups and did not change during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Summary · context
A randomized, two-arm ambulatory 16-week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3910946402
03HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In participants with type 1 diabetes, gastrointestinal symptoms were more frequent with ADO09 than with insulin lispro.
In plain wordsIn participants with diabetes, digestive symptoms were more frequent with ADO09 than with insulin lispro.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseGastrointestinal symptoms
Study
n = 80
Comparator
Insulin lispro
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal symptoms were more frequent with ADO09, but no clear difference in hypoglycaemia was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Summary · context
A randomized, two-arm ambulatory 16-week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3910946405
04HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In participants with type 1 diabetes, no clear difference in hypoglycaemia occurred between ADO09 and insulin lispro.
In plain wordsIn participants with diabetes, low blood sugar showed no clear difference between ADO09 and insulin lispro.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeHypoglycaemia
Study
n = 80
Comparator
Insulin lispro
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Gastrointestinal symptoms were more frequent with ADO09, but no clear difference in hypoglycaemia was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Summary · context
A randomized, two-arm ambulatory 16-week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3910946406
05HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In participants with type 1 diabetes, prandial insulin doses decreased by 21% in the ADO09 group.
In plain wordsIn participants with diabetes, mealtime insulin doses decreased from baseline in the ADO09 group.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePrandial insulin dose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
Prandial insulin dose reduction
21%
ADO09 group
Source sentences
Summary
Prandial insulin doses were reduced by 21% in the ADO09 group, whereas basal insulin dosage was not modified.
2 context sentences(design, population, supporting numbers)
Summary · context
To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Summary · context
A randomized, two-arm ambulatory 16-week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3910946403
06HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In participants with type 1 diabetes, basal insulin dosage did not change in the ADO09 group.
In plain wordsIn participants with diabetes, basal insulin dosage did not change from baseline in the ADO09 group.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeBasal insulin dose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Prandial insulin doses were reduced by 21% in the ADO09 group, whereas basal insulin dosage was not modified.
2 context sentences(design, population, supporting numbers)
Summary · context
To study safety, efficacy and weight loss with ADO09, a co-formulation of insulin A21G and pramlintide, in type 1 diabetes.
Summary · context
A randomized, two-arm ambulatory 16-week study compared ADO09 with insulin lispro in 80 participants with type 1 diabetes.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3910946404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.